Your session is about to expire
← Back to Search
A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)
Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Summary
This trial is testing a new drug called BMS-986278 to see if it is safe and how it affects healthy adults and Japanese participants. Researchers want to understand how the drug moves through the body and its potential side effects.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: Part 2: BMS-986278Experimental Treatment1 Intervention
Group II: Part 1: BMS-986278 + SildenafilExperimental Treatment2 Interventions
Group III: Part 2: PlaceboPlacebo Group1 Intervention
Group IV: Part 1: Placebo + SildenafilPlacebo Group2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-986278
2023
Completed Phase 2
~750
Sildenafil
2008
Completed Phase 4
~1690
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Bristol-Myers SquibbLead Sponsor
2,696 Previous Clinical Trials
4,099,010 Total Patients Enrolled